blog background

Orthopedic stem cell use expected to increase

July 28, 2015
Copied to clipboard
Stem cells could realize greater adoption as the U.S. population ages.

With so much focus on cost containment and patient satisfaction in the healthcare industry, greater innovation is needed to meet demand. Although the medical device tax continues to hold back research and development spending, a recent report by iData Research found that the orthopedic biomaterials market in particular was seeing some interesting activity, specifically in the increased use of stem cells. 

With a rapidly aging population, the U.S. is expected to see a dramatic increase in demand for orthopedic devices in coming years. Currently, the orthopedic biomaterial market is populated by treatments such as “bone graft substitutes, growth factor, orthopedic stem cells, cell therapy, hyaluronic acid viscosupplementation, cartilage repair and machined bone allografts,” the report reads. However, cost concerns have slowed the adoption of stem cell therapies, long thought to be among the most effective treatment paths. But the report notes what might be a sea change, as for the first time the orthopedic stem cell market was the fastest growing orthopedic biomaterial segment, particularly for treating the spine, and this growth could prompt greater support and interest. 

“Orthopedic stem cells’ higher average selling price is better tolerated by the commercialized nature of the spine market, explains Dr. Kamran Zamanian, CEO of iData, in the report. “As new stem cell products and innovations enter the market, prices should decline, which will aid in greater adoption and in turn fuel the number of procedures using stem cell bone grafts.”

Because of the challenges in developing protein markers and definitions to differentiate different types of stem cells, the threat of high costs has kept many stem cell treatments from reaching the clinical trial stage. But as demand rises and further clinical evidence is gained, these efforts could become more common. 

Latest Industry News

Moximed MISHA Knee System for osteoarthritis demonstrates superiority over HTO
MMI is proud to have partnered with Moximed on an FDA-regulated IDE study to investigate the safety and effectiveness of the MISHA Knee System as a treatment option for younger patients with mild to moderate OA.
DiscGenics Announces FDA RMAT Designation
The FDA granted RMAT designation to DiscGenics’ Injectable Disc Cell Therapy for degenerative disc disease.
FDA no longer requires animal tests before human drug trials
A newly signed law permits the FDA to clear a drug for human clinical trials while bypassing animal trials.